Such NFE2L1‐deficiency leads to significantly increases of CD8+ T cells and M1 macrophages within tumor tissues of glioma and hence enhances its sensitivity to anti‐PD1 therapy. The gene discussed is NFE2L1; the disease is central nervous system cancer.